Aquestive Therapeutics, Inc.
AQST
$5.39
$0.316.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 38.15% | 65.67% | 9.67% | -5.43% | -50.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.15% | 65.67% | 9.67% | -5.43% | -50.23% |
| Cost of Revenue | -11.93% | -5.01% | 29.12% | 1.56% | 0.77% |
| Gross Profit | 80.12% | 116.59% | -2.29% | -8.83% | -65.05% |
| SG&A Expenses | 10.69% | -42.44% | 105.02% | 25.76% | 11.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.14% | -33.59% | 64.48% | 11.24% | 6.62% |
| Operating Income | 27.67% | 78.29% | -112.38% | -38.47% | -20,769.09% |
| Income Before Tax | -68.76% | 64.86% | -86.65% | -34.21% | -393.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.76% | 64.86% | -86.81% | -34.21% | -393.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.76% | 64.86% | -86.81% | -34.21% | -393.55% |
| EBIT | 27.67% | 78.29% | -112.38% | -38.47% | -20,769.09% |
| EBITDA | 27.97% | 78.72% | -113.91% | -39.47% | -4,418.46% |
| EPS Basic | -34.09% | 72.64% | -39.68% | -10.52% | -351.66% |
| Normalized Basic EPS | 34.39% | 72.62% | -50.09% | -10.51% | -191.78% |
| EPS Diluted | -34.09% | 72.64% | -39.68% | -10.52% | -351.66% |
| Normalized Diluted EPS | 34.39% | 72.62% | -50.09% | -10.51% | -191.78% |
| Average Basic Shares Outstanding | 25.84% | 28.39% | 33.74% | 21.41% | 9.26% |
| Average Diluted Shares Outstanding | 25.84% | 28.39% | 33.74% | 21.41% | 9.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |